secwatch.observer — SEC 8-K summary
======================================

Issuer:     Clene Inc. (CLNN)
CIK:        0001822791
Form:       8-K
Filed at:   2026-10-19T12:05:16+00:00
Accession:  0001437749-26-032882
Event type: regulatory
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Clene submits FDA NDA for ALS drug CNM-Au8, seeking accelerated approval
------------------------------------------------------------------------

- NDA submitted to FDA earlier in October 2026 for CNM-Au8 in ALS; Clene publicly announced the submission on October 19, 2026.
- Application seeks accelerated approval based on neurofilament light chain biomarker data plus clinical outcomes.
- CEO Rob Etherington cited the FDA's "constructive engagement" and said Clene will work closely with the agency during review.
- Clene says it continues preparations for the confirmatory Phase 3 RESTORE-ALS study while the NDA is pending.
- No PDUFA date or filing-acceptance decision disclosed; FDA must accept the application before substantive review begins.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1822791/000143774926032882/0001437749-26-032882-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1822791/000143774926032882/clnn20261019_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-032882

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer